
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
WASHINGTON, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the Month of September 2017

Commission File Number: 001-38097

ARGENX SE

(Translation of registrant's name into English)

**Willemstraat 5
4811 AH, Breda, the Netherlands**
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

EXPLANATORY NOTE

Enclosed hereto and incorporated herein by reference are copies of the following items in connection with the Extraordinary General Meeting of Shareholders of argenx SE that will be held on Tuesday, November 7, 2017 at 9:00 AM (CEST), at the Sheraton Amsterdam Schiphol Airport, Schiphol Boulevard 701, 1118 BG Schiphol, the Netherlands.

Exhibit	Description
99.1	Press Release dated September 22, 2017
99.2	Convocation Notice for the Extraordinary General Meeting of Shareholders of argenx SE to be held on November 7, 2017
99.3	Explanatory Notes for the Extraordinary General Meeting of Shareholders of argenx SE to be held on November 7, 2017
99.4	Draft Remuneration Policy for the Extraordinary General Meeting of Shareholders of argenx SE to be held on November 7, 2017

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ARGENX SE

Date: September 22, 2017

By: /s/ Tim Van Hauwermeiren
Tim Van Hauwermeiren
Chief Executive Officer



Invitation to the extraordinary shareholders' meeting

September 22, 2017

Breda, the Netherlands / Ghent, Belgium — argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, has the honor to invite its shareholders, directors and statutory auditors to the extraordinary shareholders' meeting that will be held on Tuesday, November 7, 2017 at 9:00 AM CEST at the Sheraton Amsterdam Schiphol Airport, Schiphol Boulevard 701, 1118 BG Schiphol, the Netherlands.

The agenda of the extraordinary shareholders' meeting includes an update of the remuneration policy, the authorization to issue shares in the share capital and the authorization to limit or exclude pre-emptive rights regarding an issuance of new shares.

The formal notice of convocation (including information on attending the meeting in person or by proxy, requirements for notification and registration for the meeting and regarding the e-voting system) is available on argenx's website: www.argenx.com

About argenx

argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE Antibody™ Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates. www.argenx.com

For further information, please contact:

Joke Comijn, Corporate Communications Manager
+32 (0)477 77 29 44
+32 (0)9 310 34 19
info@argenx.com

Beth DelGiacco (US IR)
Stem Investor Relations
+1 212 362 1200
beth@stemir.com

Forward-looking Statements

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements." These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "intends," "may," "will," or "should," and include statements argenx makes concerning the intended results of its strategy; its financial condition, results of operation and business outlook; the sufficiency of its cash, cash equivalents and current financial assets; and the momentum of its product candidate pipeline as well as the advancement of, and anticipated clinical development and regulatory milestones and plans related to, and data readouts for, argenx's product candidates and preclinical and clinical trials. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx's actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including argenx's expectations regarding the inherent uncertainties associated with competitive developments, preclinical and clinical trial and product development activities and regulatory approval requirements; argenx's reliance on collaborations with third parties; estimating the commercial potential of argenx's product candidates; argenx's ability to obtain and maintain protection of intellectual property for its technologies and drugs; argenx's limited operating history; and argenx's ability to obtain additional funding for operations and to complete the development and commercialization of its product candidates. A further list and description of these risks, uncertainties and other risks can be found in argenx's U.S. Securities and Exchange Commission (SEC) filings and reports, including in the final prospectus related to argenx's initial U.S. public offering filed with the SEC pursuant to Rule 424(b) of the Securities Act of 1933, as amended, as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.



**EXTRAORDINARY GENERAL MEETING
OF ARGENX SE**

CONVOCAATION

argenx SE (the “**Company**”) hereby invites its shareholders and all other persons with meeting rights to attend its extraordinary general meeting of shareholders (“**EGM**”) to be held **at 9:00 AM on Tuesday 7 November 2017 at Sheraton Amsterdam Airport**, Schiphol Boulevard 101, Amsterdam, the Netherlands.

Availability of documents

The agenda of the EGM including the ancillary documentation thereto are now available for inspection at the offices of the Company or on the Company’s website (www.argenx.com). Copies of the aforementioned documents are also available to shareholders, free of charge, via ABN AMRO Bank N.V. (“**ABN AMRO**”) from today, via e-mail address: corporate.broking@nl.abnamro.com.

Shareholders’ rights, participation and voting

As of the date of this notice, the Company has 26,891,229 issued and outstanding ordinary shares, which includes 7,170,432 ordinary shares for which American Depositary Shares (“**ADSs**”) are issued. The Company’s bylaws do not have any restrictions on voting rights, each share having the right to one vote at this EGM. Voting rights may not be used for shares held by the Company itself or its subsidiaries or other shares deemed to be treasury shares. Unless Dutch law provides otherwise and with due observance of article 25 of the articles of association of the Company, all resolutions shall be passed by an absolute majority of the votes cast.

The ordinary shares are listed on Euronext Brussels and the ADSs are listed on NASDAQ. The agent for the ordinary shares is ABN AMRO and the agent for the ADSs is BNY Mellon.

Attendance at the EGM

Only holders of ordinary shares in the share capital of the Company as of the close of business on 28 days prior to the EGM, being Tuesday 10 October 2017 (the “**Record Date**”) or those who hold a valid proxy for the EGM are entitled to take part in and vote at the EGM. Each ordinary share outstanding on the Record Date is entitled to one vote on each voting item.

Holders of ordinary shares and all other persons with meeting rights who either in person or by proxy wish to attend the meeting must notify ABN AMRO accordingly by 17.00 CET on Thursday 2 November 2017 at the latest via their financial intermediary as defined in the “*Wet giraal effectenverkeer*” or their agent (the “**Intermediary**”) or directly via www.abnamro.com/evoting.

The Intermediary concerned must submit to ABN AMRO no later than Friday 3 November 2017, 12.00 CET, a statement via www.abnamro.com/intermediary, including the number of deposit shares notified for registration and held by that shareholder at the Record Date. With this statement, intermediaries are furthermore requested to include the full address details of the relevant holder in order to be able to

verify the shareholding on the Record Date in an efficient manner. The proof of registration supplied by ABN AMRO will serve as admission ticket to the meeting.

Persons entitled to take part in the meeting may be asked to identify themselves prior to being admitted to the EGM and are therefore asked to carry valid proof of identification.

Voting by (electronic) proxy

A holder of ordinary shares who chooses to be represented at the meeting shall, in addition to submitting the application to attend the meeting as described above, grant a proxy. The proxy may include a voting instruction. Holders of ordinary shares may grant a proxy and give voting instructions to argenx SE via www.abnamro.com/evoting by 17.00 CET on Thursday 2 November 2017 at the latest.

Alternatively, a proxy may be granted in writing. A written proxy may be granted to a third party or a representative of the Company. The duly signed written proxy, which can be downloaded from the Company's website or obtained via e-mail annualmeeting@argenx.com or telephone +32 9 241 58 41. must be received by 17.00 CET on Thursday 2 November 2017 at the latest by the Company via e-mail annualmeeting@argenx.com.

Right to ask questions

All holders of ordinary shares are entitled to ask questions to the Board with respect to the agenda items. Questions may be asked during the EGM, or may be submitted in writing by shareholders who have fulfilled the registration and admission formalities set out above, to the Company e-mail address prior to the EGM ultimately on Thursday 2 November 2017.

Holders of ADSs

Holders of ADSs will receive information about the EGM and how to attend, exercise their voting rights and other rights via their custodian from BNY Mellon (as the holder of the shares for which the ADSs are issued).

Breda, [22] September 2017
Board of directors argenx SE



**EXTRAORDINARY GENERAL MEETING
OF ARGENX SE**

EXPLANATORY NOTES

The following items on the agenda of the meeting shall be discussed and/or put to a vote. The numbers in the list correspond to the numbers on the agenda.

1. Amendment of the remuneration policy (*voting item*)

The actual remuneration policy was adopted by the general meeting of shareholders on 28 April 2016. In line with the actual remuneration policy, the board of directors has considered the appropriateness of the Reference Group (as defined in the remuneration policy) and the market level of remuneration, taking into account the further development and evolution of argenx SE (the *Company*). The conclusions of this review resulted in an update of the remuneration policy in order to appreciate the contribution of the board committees as well as to properly reflect the US component of the Company's activities.

2. Authorization of the board of directors to issue shares in the share capital of the Company up to a maximum of 20% of the outstanding capital at the date of the general meeting, for a period of 18 months from the general meeting (*voting item*)

This agenda item proposes to replace the currently existing authorization of the board of directors to issue shares in the share capital of the Company up to a maximum of 20% of the outstanding capital with a new authorization to designate the Board as the corporate body competent to issue ordinary shares in the capital of the Company and grant rights to subscribe for ordinary shares in the capital of the Company at any time during a period of 18 months as of the date of this general meeting up to a maximum of 20% of the issued share capital of the Company, to be calculated against the amount of issued share capital as it will be at the date of this general meeting. For the avoidance of doubt: this authorization is in addition to the current authorization to issue shares pursuant to the exercise of stock options.

3. Authorization of the board of directors to, insofar necessary, limit or exclude pre-emptive rights regarding an issuance of new shares for a period of 18 months from the general meeting (*voting item*)

This agenda item proposes to grant the board of directors the authority to limit or exclude pre-emptive rights in relation to any issuance of shares to which the board of directors may resolve as authorized under 2. above.



argenx SE.

DRAFT REMUNERATION POLICY

This amended remuneration policy for the executive directors and non-executive directors of the board of directors (the **Board**) of argenx SE (the **Company** or **argenx**) and the C-level management of argenx (the **Management**) has been proposed to the general meeting of shareholders of [7] November 2017 and will apply retroactively from 1 January 2017.

Introduction

The remuneration of each director of the Board and Management shall be determined by the non-executive directors, at the recommendation of the remunerations and nominations committee, within the limits of this remuneration policy. Such proposal shall, in any event, deal with:

- (i) the remuneration structure; and
- (ii) the amount of the fixed remuneration, the shares and/or options to be granted and/or other variable remuneration components, pension rights, redundancy pay and other forms of compensation to be awarded, as well as performance criteria and their application.

The executive director(s) shall not participate in the decision-making of the Board regarding the determination of the remuneration.

The objective of the remuneration policy

This remuneration policy is aimed to attract, reward and retain highly qualified executives directors, non-executive directors and managers and to provide and motivate the members of the Board and Management with a balanced and competitive remuneration that is focused on sustainable results and is aligned with the long-term strategy of the Company.

Reference group and market positioning

For as long as argenx qualifies within the group of comparable (biotech) companies of more or less the same size and comparable corporate development stage (the **Reference Group**), the chosen market level of remuneration payable within the Reference Group will serve as a reference in determining the level of pay for the members of the Board.

The remuneration and nomination committee shall annually evaluate the relevance of the selection and if needed adapt the Reference Group, thereby ensuring a minimum of eight comparable companies. Every other year, the Board considers the appropriateness of any change of base and/or variable salary in the context of the market environment as well as the salary adjustments for other argenx employees.

Remuneration components executive directors and Management

The remuneration of the executive director(s) and Management consists of the following fixed and variable components:

- a fixed base salary;
 - a variable annual bonus (short-term annual incentive);
-

- a long-term variable incentive plan, in the form of stock options;
- pension and fringe benefits; and
- severance arrangements.

Fixed base salary

The base salary of Management members living in Europe will be determined at a range around or slightly above the 75th percentile salary level within the European companies of the Reference Group, whereas the 50th percentile salary level of US based companies in the Reference Group will be the reference for Management members living in the United States. The base salary of the chief executive officer will be determined at a range around or slightly above the median salary levels payable within a blend of both European and US companies of the Reference Group.

Variable annual cash bonus

The objective of this short term annual cash incentive is to ensure that the executive director(s) and Management are well incentivized to achieve performance targets in the shorter term.

An executive director or Management member will be eligible for an annual cash incentive up to a maximum percentage of his/her annual base salary. Performance conditions will be set by the Board before or ultimately at the beginning of the relevant calendar year and shall include criteria concerning the Company's financial performance, qualitative criteria representing Company performance and/or individual qualitative performance.

Long-term incentive plan

The Board intends to incentivize the executive director(s) and Management through the granting of stock options under the argenx stock option plan and by establishing amended forms thereof or other stock option plans or similar plans from time to time to align the longer term interests of the executive director(s) and Management members with those of the shareholders and to provide an incentive for longer term focus and retention of executive directors and Management.

Pension and fringe benefits

The executive director(s) and Management members shall (continue to) participate in a defined contribution pension scheme operated by a third party pension insurance organization.

The executive director(s) and Management members are entitled to customary fringe benefits, such as a company car.

Severance arrangements

In case of termination of employment or management agreement other than for cause, executive directors and Management members will be entitled to a severance payment in line with market practice in the Reference Group. The conditions of the severance are included in the management or employment contracts and are based on a recommendation of the remuneration and nomination committee. The severance arrangement may also include an accelerated vesting of outstanding stock options.

Remuneration components non-executive directors

The remuneration of the non-executive directors consists of the following components:

- a fixed fee, which fee will be prorated in case the director does not attend all meetings where his or her presence is required;
 - if applicable, a fee for chairman and the members of the audit committee, the research & development committee and/or the remuneration and nomination committee; and
 - a long-term variable incentive, in the form of stock options.
-

The goal is that the cash component represents one third and the long-term variable incentive two thirds of the total compensation of the non-executive directors.

Fixed fee

The fixed fee of non-executive directors will be determined at a range around or slightly above the median of fees payable within the Reference Group, including both European and US based companies.

Long-term incentive plan

The Board intends to incentivize the non-executive directors through the granting of stock options under the argenx stock option plan and by establishing amended forms thereof or other stock option plans or similar plans from time to time to be able to attract and retain well-qualified non-executive directors.

Success payment

In case of exceptional circumstances, the Board may decide to reward non-executive directors success payments relating to the occurrence of specific events achieved through the exceptional efforts of that person (such as a platform licensing or product licensing deal brokered by that non-executive director).

General

Discretionary adjustments

The Board has the authority to deviate from the policies set out herein fore, in case it considers it necessary or desirable to do so in specific individual cases in order to attract and retain the most qualified directors also in the future. The remuneration policy of the Board is reassessed each year by the remuneration and nomination committee.

Loans and guarantees

No personal loans or guarantees, including mortgage loans, are offered to any of the directors of the Board.

Claw back

The Company is authorized to partially or fully claim back any variable cash bonus paid to the extent that such variable cash bonus was paid out on the basis of erroneous information about the achievement of the performance targets underlying such variable cash bonus.
